Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia.
The diurnal change of sUA and the effect of febuxostat on this change were investigated in 10 patients with gout and/or hyperuricemia. The diurnal sUA change after the last dose during the 4-week treatment phase (20 mg, QD) was almost the same as the pre-treatment value. Considering the dose, the AUC(obs) and Cmax of unchanged drug in patients with gout and/or hyperuricemia were estimated to be similar to those of healthy male adults. The results show that a 6-week treatment with febuxostat is safe and well-tolerated in the target patient population for this drug.
Komoriya
K
K
Teijin Ltd., Tokyo, Japan.
Hoshide
S
S
Takeda
K
K
Kobayashi
H
H
Kubo
J
J
Tsuchimoto
M
M
Nakachi
T
T
Yamanaka
H
H
Kamatani
N
N
D019540:Area Under Curve; D004791:Enzyme Inhibitors / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D000069465:Febuxostat; D006073:Gout / Q000188:drug therapy*; D006801:Humans; D033461:Hyperuricemia / Q000188:drug therapy*; D008297:Male; D010100:Oxygen / Q000378:metabolism; D013844:Thiazoles / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D013997:Time Factors; D014968:Xanthine Dehydrogenase / Q000037:antagonists & inhibitors; D014969:Xanthine Oxidase / Q000037:antagonists & inhibitors
D004791:Enzyme Inhibitors; D013844:Thiazoles; D000069465:Febuxostat; D014968:Xanthine Dehydrogenase; D014969:Xanthine Oxidase; D010100:Oxygen